Nature Reviews Drug Discovery 5, 919-931 (November 2006) | doi:10.1038/nrd2136

The obesity pipeline: current strategies in the development of anti-obesity drugs

Dunstan Cooke1 & Steve Bloom1,2  About the authors


This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.

Author affiliations

  1. Thiakis Limited, Imperial BioIncubator, Bessemer Building (RSM), Prince Consort Road, London SW7 2BP, UK.
  2. Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK.

Correspondence to: Steve Bloom1,2 Email:


These links to content published by NPG are automatically generated.


Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity

Nature Clinical Practice Gastroenterology & Hepatology Review (01 May 2008)

The role of oxyntomodulin and peptide tyrosine???tyrosine (PYY) in appetite control

Nature Clinical Practice Endocrinology & Metabolism Review (01 Nov 2006)

Bowels control brain: gut hormones and obesity

Nature Reviews Endocrinology Review (01 Aug 2010)

See all 26 matches for Reviews


Cellular energy sensor balances the scales

Nature Medicine News and Views (01 Jul 2004)